Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
Shares of Genmab (NASDAQ:GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net ...
Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...
Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...
Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...
BNP Paribas upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a strong sell rating to a hold rating in a report issued on Tuesday morning,Zacks.com reports. GMAB has been the subject of a ...
Media ReleaseCOPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report ...
Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice ...
Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports.
Genmab AS (GMAB) reports a 31% revenue increase and outlines strategic plans for 2025 amidst competitive market challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results